A diabetes drug candidate that got its start in an entomology lab at the University of California, Davis, has taken another step toward commercialization.

Arete Therapeutics, which spun out of UC Davis earlier this decade to develop drug candidates based on discoveries by entomology professor Bruce Hammock, said last month that it has commenced Phase II clinical trials for the compound, an oral inhibitor of an enzyme that metabolizes a key signaling molecule implicated in diabetes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.